NCT07054398 Assessment of Serum Catestatin Level in Acne Vulgaris Patients
| NCT ID | NCT07054398 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aswan University |
| Condition | Acne Vulgaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-01-10 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-01-10 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
Eligibility Criteria
Inclusion Criteria: * Healthy persons of both sexes with moderate and severe acne. Exclusion Criteria: * Pregnant and lactating women. * Immunocompromised patients. * Severe anemia. * History of chronic liver disease. * Hyperlipidemia * Non-inflammatory acne conditions. * History of neurologic disorders. * History of neoplastic disorders. * History of cardiac disease. * History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks. * Cases with known hypersensitivity reaction to isotretinoin.
Contact & Investigator
Moustafa Adam Ali El Taieb, Professor
STUDY CHAIR
Dermatology, Venereology and Andrology. Faculty of Medicine,Aswan University
Frequently Asked Questions
Who can join the NCT07054398 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Acne Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07054398 currently recruiting?
Yes, NCT07054398 is actively recruiting participants. Contact the research team at mona1704213@aswu.edu.eg for enrollment information.
Where is the NCT07054398 trial being conducted?
This trial is being conducted at Aswān, Egypt.
Who is sponsoring the NCT07054398 clinical trial?
NCT07054398 is sponsored by Aswan University. The principal investigator is Moustafa Adam Ali El Taieb, Professor at Dermatology, Venereology and Andrology. Faculty of Medicine,Aswan University. The trial plans to enroll 60 participants.